isabelobrien, Author at European Medical Journal - Page 24 of 68

The word spotlight on a blue background

Spotlight: February 2025

From a historic vaccine approval to a $50bn investment reshaping US drug manufacturing, February brought major pharma news to the fore.

UK's NHS must boost medicine spending, ABPI warns

The UK must increase investment in innovative medicines and vaccines if it is to deliver on the NHS 10-Year Plan and drive economic growth.

Angelo Auricchio

Boston Scientific’s Angelo Auricchio on what’s next for heart health

Discover what’s on the horizon for cardiac care and remote monitoring with Angelo Auricchio, Chief Medical Officer, Rhythm Management, Boston Scientific.

White House

Trump administration cuts more than 90% of USAID funding

The Trump administration is set to cut a total of $60bn in US assistance worldwide, signalling a major shift in health policy.

Eli Lilly plans record $50bn US manufacturing investment

The company’s investment will expand its US manufacturing footprint and is the largest investment of its kind in history.

Eytan Stein

Hema Now: Episode 11: Decoding Leukaemia's Epigenetic Drivers

Eytan Stein, Chief of the Leukaemia Service; Attending Physician, Memorial Sloan Kettering Cancer Center, New York, USA

Chiesi’s Enrico Piccinini on driving action for Rare Disease Day

Find out what the Senior Vice President, EU & International, Rare Diseases, Chiesi Group, thinks the pharma industry should consider on Rare Disease Day.

HBA CEO Mary Stutts

The HBA’s Mary Stutts on tackling bias for better women’s health

Mary Stutts, CEO, HBA, unpacks the key findings of a report exposing critical gaps in doctors’ understanding of women’s health.

The world

EMA grants accelerated review to Gilead’s PrEP drug

The EMA is set to perform accelerated reviews of Gilead Sciences’ applications for its twice-yearly injectable for HIV prevention.

Handshake on a green background

AstraZeneca pays $160m for FibroGen's China subsidary

FibroGen, Inc. has announced the sale of its Chinese subsidiary to AstraZeneca, including the rights to roxadustat in China.